Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10001779HBVENSG00000115594.12protein_codingIL1R1NoNo3554B8ZZW4
P14778
TVIS10023576HBVENSG00000115594.12protein_codingIL1R1NoNo3554B8ZZW4
P14778
TVIS10028623HBVENSG00000115594.12protein_codingIL1R1NoNo3554B8ZZW4
P14778
TVIS20039380HPVENSG00000115594.12protein_codingIL1R1NoNo3554B8ZZW4
P14778
TVIS20055489HPVENSG00000115594.12protein_codingIL1R1NoNo3554B8ZZW4
P14778
TVIS44008101HTLV-1ENSG00000115594.12protein_codingIL1R1NoNo3554B8ZZW4
P14778
TCGA Plot Options
Drug Information
GeneIL1R1
DrugBank IDDB00026
Drug NameAnakinra
Target IDBE0000565
UniProt IDP14778
Regulation Typeantagonist
PubMed IDs17498496; 12817089; 12355453; 17083033; 11752352; 17352828; 10210771
CitationsTang YH, Zhang SP, Liang Y, Deng CQ: [Effects of Panax notoginseng saponins on mRNA expressions of interleukin-1 beta, its correlative factors and cysteinyl-aspartate specific protease after cerebral ischemia-reperfusion in rats]. Zhong Xi Yi Jie He Xue Bao. 2007 May;5(3):328-32.@@Dayer JM: The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology (Oxford). 2003 May;42 Suppl 2:ii3-10.@@Vamvakopoulos J, Green C, Metcalfe S: Genetic control of IL-1beta bioactivity through differential regulation of the IL-1 receptor antagonist. Eur J Immunol. 2002 Oct;32(10):2988-96.@@Do H, Vasilescu A, Carpentier W, Meyer L, Diop G, Hirtzig T, Coulonges C, Labib T, Spadoni JL, Therwath A, Lathrop M, Matsuda F, Zagury JF: Exhaustive genotyping of the interleukin-1 family genes and associations with AIDS progression in a French cohort. J Infect Dis. 2006 Dec 1;194(11):1492-504. Epub 2006 Oct 26.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@So A, De Smedt T, Revaz S, Tschopp J: A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9(2):R28.@@Vannier E, Kaser A, Atkins MB, Fantuzzi G, Dinarello CA, Mier JW, Tilg H: Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapy. Eur Cytokine Netw. 1999 Mar;10(1):37-42.
GroupsApproved; Investigational
Direct ClassificationPeptides
SMILES
Pathways
PharmGKBPA10799
ChEMBLCHEMBL1201570